Table 1.

Studies reporting the effect and safety of sorafenib after liver transplantation for recurrent hepatocellular carcinoma

Ref.	Design	Population	SOR/BSC	mTOR	SOR duration(mo)	Adverse events with SOR	PRS with SOR (mo)
Bhoori et al[16]	Case report	Single patient with HCC recurrence	1 (1/-)	1/1	4	HFS	8
Yoon et al[47]	Retrospective cohort	HCC-R with SOR median TTR (12.3 mo)	13 (13/-)	1/13	2.4	HFS	5.4
Kim et al[48]	Retrospective cohort	HCC-R with SOR	9 (9/-)	7/9	2.8	-	-
Staufer et al[49]	Retrospective cohort	HCC-R with SOR	20 (13/7)	9/18	5.5	Grade 3-4 92%. Diarrhea 77% Discontinuation	19
Gomez-Martín et al[50]	Retrospective cohort	HCC-R with SOR + mTOR median TTR (22.6 mo)	31 (31/-)	31/31	-	Diarrhea	19
Weinmann et al[51]	Retrospective cohort	HCC-R with SOR median TTR (37.5 mo)	11 (11/-)	9/11	8.9	Diarrhea	20
Vitale et al[52]	Retrospective cohort	HCC-R with SOR median TTR (7 mo)	27 (10/-)	10/27	10	Diarrhea 30%, Discontinuation	18
Zavaglia et al[53]	Retrospective cohort	HCC-R with SOR	11 (11/-)	7/11	2.2	Fatigue	5
Waghrayet al[54]	Retrospective cohort	HCC-R	34 (17/17)	10/34	10.2	Diarrhea	7
Sposito et al[30]	Retrospective cohort	HCC-R with SOR	39 (15/24)	7/39	6.9	HFS	10.6 vs 2.2 median TTR 20.6 vs 15.5 mo
Alsina et al[55]	Retrospective cohort	HCC-R with/without SOR	22 (9/13)		10.2	Rash	42 vs 16 since LT

PRS: Post-recurrence survival; HCC: Hepatocellular carcinoma; TTR: Time to recurrence; LT: Liver transplantation; HFS: Hemifacial spasm.